Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenex SE $ARGX Shares Purchased by Yousif Capital Management LLC
04:36am, Thursday, 23'rd Oct 2025
Yousif Capital Management LLC boosted its position in argenex SE (NASDAQ: ARGX) by 12.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission
INCY or ARGX: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 16'th Oct 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
01:00am, Wednesday, 15'th Oct 2025
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART's sustained
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
04:01pm, Friday, 03'rd Oct 2025
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
INCY vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 30'th Sep 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for
Are Medical Stocks Lagging Argenx (ARGX) This Year?
10:40am, Tuesday, 23'rd Sep 2025
Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
09:00am, Thursday, 18'th Sep 2025
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a s
argenx SE - Special Call
09:23pm, Tuesday, 16'th Sep 2025
argenx SE - Special Call Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Roeland Vanhauwaert Peter Ulrichts - Chief Scientific Officer Luc Tru
argenx: Bullish On This R&D Focused Biotech Stock
04:16am, Friday, 12'th Sep 2025
argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
03:32pm, Wednesday, 03'rd Sep 2025
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
KMDA or ARGX: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 01'st Sep 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two companies is the best option
3 Healthcare Pathbreakers With Long-Term Tailwinds
12:21pm, Monday, 01'st Sep 2025
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and
argenx to Present at Upcoming Investor Conferences
01:00am, Thursday, 28'th Aug 2025
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
01:35pm, Tuesday, 26'th Aug 2025
Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab)
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
01:00am, Monday, 25'th Aug 2025
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronega
